Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

13 November 2020
Pharma

Visiongain has published a new report on Biological Imaging Reagents Market Report 2021-2031: Forecasts By Product Type (Contrast Reagents, Nuclear Reagents, Optical Imaging Reagents, Fluorescent Dyes and Probes, and Others Reagents), By Form (Injectable, Tablet, Suspension, and Others), By Application (In Vitro, and In Vivo), By Technology Type (Nanotechnology, Biologic Targeting, Microfluidics, Supramolecular Chemistry, Protein Engineering, and Others), By End-User (Diagnostic Laboratories, Imaging Centers, Life Sciences Companies, Academic & Research Institutes, and Others), By Distribution Channel (Direct Tender, and Retail Sales), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global biological imaging reagents market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Biological Imaging Reagents market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Biological Imaging Reagents Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Biological Imaging Reagents market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing prevalence of Cardiovascular Diseases
Cardiovascular diseases prevalence has increase in past few years and is expected to rise over the forecast period. For Instance: according to world health organisation approximately 17.9 million people died from Cardiovascular Diseases in 2016 which is representing 31% of all global deaths. Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

Increasing Number of Diagnostic Imaging Procedures
Diagnostic imaging procedures usage has increased significantly from last few years, contributing to medical exposure and medical costs to ionizing radiation. Diagnostic imaging procedures is continuously increasing around the world due to increasing awareness and government initiatives for availability of treatment and diagnosis of life threatening diseases. Increasing number of diagnostic imaging procedures is raising the demand of the biological imaging reagent around the world.

Market Opportunities

Technological Advancements in Biological Imaging Reagents
Biological imaging is used to characterize, visualize, and measure of biological processes at the subcellular, cellular level to determine stages of disorders and diseases. Biological imaging reagents have rapidly gaining the significance in the dawning era of personalized medicine. Biological imaging reagents comprise advantages and few side effects of the traditional diagnostic imaging which is leading the manufactures to increasing research and development activities in the order to overcome side effects associated with the biological imaging reagents. Technological advancements in biological imaging reagents is expected to increase the adoption and to create new opportunities for the biological imaging reagents in the forecasted period.

Increasing Strategic initiatives in Biological Imaging Reagents market
Manufactures present in the biological imaging reagents market are focusing on acquisition of new regulatory approvals and licenses, mergers & acquisition, product launches in the order to increase the demand and availability of the biological imaging reagents in the market. These strategic initiatives are expected to create competitive advantage for the players in the market and increase their market share in the biological imaging reagents market.

Competitive Landscape
Top companies (Bayer AG, Thermo Fisher Scientific, Inc., PerkinElmer, Inc.) constitute more than XX% share of the global Biological Imaging Reagents market. Other companies profiled in the report include: Guerbet, Lantheus Holdings, Inc., Bracco S.p.A., GE Healthcare, BD, Siemens Healthineers, Luminex Corporation among others. Some of the key developments are listed below:
• In 2019, Bayer AG has received FDA approval for Gadavist (gadobutrol) injection especially designed for usage in cardiac magnetic resonance (MR) imaging to assess late gadolinium enhancement and myocardial perfusion (stress, rest) in adult patients with known or suspected coronary artery disease (CAD). Gadavist (gadobutrol) injection is the only FDA approved agent for usage in cardiac magnetic resonance (MR) imaging. Through this development company will widened their market focused product portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever